Bionor Pharma ASA (OSE: BIONOR) announces that the results from the Company’s first re-boost clinical trial of Vacc-4x have been accepted for publication in the renowned journal Vaccine.
The Phase II trial was conducted at Oslo University Hospital and completed in 2010. The trial investigated the effect of re-boosting 22 available patients from previous study with the Company’s leading therapeutic HIV vaccine candidate Vacc-4x. The study demonstrated that it is possible to elicit strong memory immune responses up to 7 years after the initial vaccination.
If you would like to read more, visit Bionor Pharam's website here.